Mayinglong Pharmaceutical Group Co., Ltd. Class A

Mayinglong Pharmaceutical Group Co., Ltd. Class A

SSSE:600993
26.20
CNY
+0.96
(+3.80%)
1.44EPS
16.35P/E
9.71BMarket Cap
Mar 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.7
3.78
4.15
4.87
4.05
5.11
6.31
6.46
7.87
8.19
7.29
8.68
8.98
9.24
Basic EPS, GAAP
0.43
0.47
0.52
0.58
0.74
0.41
0.84
0.97
1.08
1.11
1.03
1.23
1.35
1.38
Free Cash Flow per Basic Share
0.11
0.01
0.14
0.4
0.73
0.66
1.04
0.55
1.24
0.62
0.83
0.68
1.12
- -
Dividend per Share
0.13
0.15
0.04
0.21
0.2
0.24
0.16
0.27
0.29
0.38
0.38
0.41
0.63
0.7
Book Value per Share
3.31
3.64
4.14
4.5
5.09
5.26
5.92
6.61
7.36
8.11
8.67
9.43
10.16
10.65
Tangible Book Value per Share
3.22
3.53
4.02
4.38
4.97
5.13
5.81
6.41
7.14
7.86
8.24
8.91
9.58
10.05
Basic Weighted Avg Shares
433
429
429
431
433
430
429
432
430
431
430
429
431
432
Sales/Revenue/Turnover
1,602
1,621
1,784
2,103
1,751
2,198
2,705
2,792
3,385
3,532
3,137
3,728
3,867
3,990
Operating Margin (%)
11.71
11.61
11.7
11.09
15.81
14.48
14.44
13.76
14.01
14.91
13.27
16.6
17.32
17.32
Depreciation Expense
25
24
24
36
36
36
36
35
69
79
81
81
94
- -
Net Income, GAAP
186
201
223
250
320
176
360
419
465
479
443
528
581
595
Effective Tax Rate (%)
17.39
13.52
14.86
16.69
15.35
14.17
16.34
13.47
13.52
14.27
13.89
16.62
14.57
14.7
Profit Margin (%)
11.63
12.43
12.52
11.9
18.28
8.02
13.31
15.01
13.72
13.55
14.13
14.17
15.04
14.91
Working Capital
1,128
1,167
1,244
1,382
1,726
1,804
2,100
2,281
2,696
3,368
3,091
3,171
3,040
2,903
LT Debt
- -
- -
- -
5
4
3
5
76
73
522
194
76
70
51
Total Equity
1,566
1,699
1,887
2,017
2,271
2,347
2,631
2,947
3,314
3,616
3,870
4,201
4,515
4,723
Return on Invested Capital (%)
10.5
10.64
10.54
10.84
13.68
6.81
13.39
14.08
13.63
11.86
10.75
12.79
13.4
13.19
Return on Capital (%)
12.89
12.78
12.97
13.31
15.15
8.21
14.7
14.12
13.89
12.59
10.7
11.99
12.46
12.37
Return on Common Equity (%)
13.72
13.45
13.31
13.44
15.49
7.91
14.94
15.51
15.43
14.36
12.26
13.53
13.77
13.62

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
30
33
20
LT Borrowings
- -
- -
- -
LT Finance Leases
74
61
51
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
431
431
431
Market Capitalization
10,841
9,319
9,707

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,802
3,680
3,698
Cash, Cash Equivalents & STI
2,561
2,477
2,399
Accounts Receivable, Net
294
481
411
Inventories
269
268
301
Total Current Liabilities
751
1,045
795
Payables & Accruals
- -
- -
- -
ST Debt
30
33
20
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.16%
8.93%
7.46%
Free Cash Flow
43.06%
30.75%
63.76%
Net Income, GAAP
15.15%
7.15%
10.11%
Sales/Revenue/Turnover
8.99%
7.4%
3.72%
Total Cash Common Dividend
56.94%
19.98%
52.1%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
955
973
864
936
3,728
2025
969
980
- -
1,029
3,867
2026
1,012
999
949
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.46
0.27
0.34
0.16
1.23
2025
0.47
0.32
- -
0.19
1.35
2026
0.49
0.35
0.35
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.39
0.01
0.41
2025
- -
- -
- -
- -
0.63
2026
- -
- -
0.7
- -
- -

Company Description

CEO
You Zhang Xia
Full Time Employees
2,544
Sector
Health technology
Industry
Pharmaceuticals: major
Address
100 Zhoujia Wan Wuhan HB China 430064
IPO Date
May 17, 2004
Business
Mayinglong Pharmaceutical Group Co., Ltd. specializes in the development, production, and sale of pharmaceuticals and health products, primarily focusing on anorectal health solutions. The company offers a broad range of products including proprietary medicines such as Ma Yinglong Musk Hemorrhoids Ointment and Suppository, Longzhu ointment, functional cosmetics (eye care, facial and body cleaning products), functional care items (infant paper, skin care, feminine products), functional foods that enhance digestion and kidney health, as well as medical devices and dietary supplements. Additionally, Mayinglong operates in hospital medical services and management, retail and wholesale of medical devices and pharmaceuticals, and provides hospital operations mainly across China. Founded in 1582 and headquartered in Wuhan, China, Mayinglong maintains significant market share in the domestic hemorrhoid treatment segment, with over 40% share and widespread brand recognition. In the recent 1-2 years, Mayinglong has pursued strategic growth through acquisitions and expansions including a notable acquisition of a 60% stake in Jiangxi Shuanghe Pharmaceutical Co., Ltd., enhancing its production capacity. The group also entered into a partnership involving the sale of an 86.816% stake in Shenzhen Daphne Pharmaceutical Co., Ltd. to Hangzhou Yunbai Pharmaceutical Technology Co., Ltd., reflecting active portfolio management. Mayinglong continues to invest heavily in research and development, allocating around 8-10% of annual revenue to innovate and expand its product portfolio, which includes over 60 formulations sold domestically and internationally. In 2023, the company launched over 30 new products and expanded its international footprint to more than 50 countries with certifications including GMP and ISO standards. Its revenue streams are diversified across traditional Chinese and Western medicines, over-the-counter products, prescription drugs, and healthcare services, supporting a balanced business model that integrates traditional medicine with modern pharmaceutical practices. The company emphasizes digital sales channels and brand awareness campaigns, having boosted its marketing budget significantly to reach broader markets domestically and abroad, particularly targeting Southeast Asia and Europe. Its comprehensive three-dimensional industrial structure comprises pharmaceuticals, medical services, pharmaceutical commerce, and hospital management. Mayinglong’s persistent innovation in formulations, market expansion, and strategic alliances underpin its leadership role in China’s pharmaceutical and healthcare industry.